Frontiers in Natural Product Chemistry

Editor: Atta-ur-Rahman, *FRS*

Bentham Books

Frontiers in Natural Product Chemistry

(Volume 8)

Edited by

Atta-ur-Rahman, FRS

Kings College University of Cambridge Cambridge UK

Frontiers in Natural Product Chemistry

(Volume 8)

Editor: Prof. Atta-ur-Rahman, FRS

ISSN (Online): 2212-3997

ISSN (Print): 1574-0897

ISBN (Online): 978-1-68108-937-9

ISBN (Print): 978-1-68108-938-6

ISBN (Paperback): 978-1-68108-939-3

©2021, Bentham Books imprint.

Published by Bentham Science Publishers - Sharjah, UAE. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (**"Work"**). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

- 1. All rights reserved: The Work is 1. the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
- 2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
- 3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

2. Your rights under this License Agreement will automatically terminate without notice and without the

^{1.} Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2 PO Box 7917, Saif Zone Sharjah, U.A.E. Email: subscriptions@benthamscience.org



CONTENTS

IST OF CONTRIBUTORS	
CHAPTER 1 CHEMISTRY, ANTIVIRAL PROPERTIES AND CLINICAL RELE	VANCE OF
IARINE MACROALGAE AND SEAGRASS	
Satarupa Acharjee, Sabyasachi Banerjee and Sankhadip Bose	
INTRODUCTION	
REASON OF SPECIAL INTEREST IN MACROALGAE AND SEAGRASS A	S NOVEL
ANTIVIRALS	
ADJUVANT ROLE OF ALGAL BIOPOLYMERS IN ANTIVIRAL VACCIN	ES
TYPES OF MACROALGAE/SEAWEEDS	
Green Algae	
Brown Algae	
Rhodophyta (Red Algae)	
CHEMISTRY OF MARINE METABOLITES HAVING ANTIVIRAL ACTIV	ITY
Sulfated Polysaccharides	
Fucoidans	
Carrageenans	
Ulvans	
Lectins	
Diterpenes	
Polyphenols	
Glycolipids	
EXPERIMENTAL AND CLINICAL STUDIES ON ANTIVIRAL ACTIVITIE	S OF
SECONDARY METABOLITES OF SEAWEEDS AND SEAGRASS POST 20	10
Glycolipid	
Lectins	
Polyphenols	
Sulfated Polysacchrides	
Tannins	
Terpenes	
Seagrass	
CONCLUSION AND FUTURE PERSPECTIVES	
CONSENT FOR PUBLICATION	
CONFLICT OF INTEREST	
ACKNOWLEDGEMENTS	
REFERENCES	
CHAPTER 2 QUINOLIZIDINE ALKALOIDS FROM MARINE ORGANISMS: A	
ERSPECTIVE ON CHEMICAL, BIOACTIVITY AND SYNTHESIS	
Archana Singh, Supriya Tilvi and Keisham S. Singh	
INTRODUCTION	
QUINOLIZIDINE ALKALOIDS (QAS) FROM MARINE SPONGES	
QUINOLIZIDINE ALKALOIDS (QAS) FROM MARINE SPONGES QUINOLIZIDINE ALKALOIDS FROM ASCIDIANS	
QUINOLIZIDINE ALKALOIDS FROM FUNGI	M M A DINE
QUINOLIZIDINE ALKALOIDS FROM FUNGI SYNTHESIS ASPECTS OF QUINOLIZIDINE ALKALOIDS DERIVED FRO	
QUINOLIZIDINE ALKALOIDS FROM FUNGI SYNTHESIS ASPECTS OF QUINOLIZIDINE ALKALOIDS DERIVED FRO ORGANISMS	
QUINOLIZIDINE ALKALOIDS FROM FUNGI SYNTHESIS ASPECTS OF QUINOLIZIDINE ALKALOIDS DERIVED FRO	

Total Synthesis by Baldwin et al. [53]	63
Synthesis of Clavepictines A & B (43 & 44) and Pictamine (45)	
Synthesis by Ha and Cha	
Electrophilic Cyclization of δ-Amino Allene	
Synthesis of cLavepictines and Pictamine	
Total Synthesis of Citrinadins A (46) and B (47) and their Structural Revision	
Synthesis of Citrinadin A (46) by Bian et al	77
Synthesis of Citrinadin B by Kong et al.	
Total Synthesis of Citrinadin A and citrinadin B by Bian et al.	
Synthesis of Citrinadin B (47)	
CONCLUSION	
LIST OF ABBREVIATIONS	92
CONSENT FOR PUBLICATION	93
CONFLICT OF INTEREST	93
ACKNOWLEDGEMENTS	93
REFERENCES	93
CHAPTER 3 TOWARDS THE USE OF WHOLE NATURAL PRODUCTS IN PSYCHEDE	
	LIC 99
Genís Ona and José Carlos Bouso	99
INTRODUCTION	99
INTRODUCTION INTERACTIONS BETWEEN COMPOUNDS IN NATURAL PRODUCTS AND THEI	
MULTI-TARGET EFFECTS	
Interactions in Natural Products	
Methods for Assessing Interactions and Synergism	
Multi-target Effects of Natural Products: Towards the Polypharmacology Paradigm	
Why Natural Products Modulate Multiple Targets	
A Symphony Cannot be Whistled. It Takes a Whole Orchestra to Play it	
RECENT DEVELOPMENTS IN THE THERAPEUTIC USE OF PSYCHOACTIVE	
ETHNOBOTANICALS	112
Mechanisms of Action of Psychoactive Ethnobotanicals	
Neuroimaging Research	
Anti-inflammatory Effects	
Neuroendocrine Effects	
Psychological Effects	120
Microdosing as an Emerging Trend	120
REASONS FOR USING WHOLE NATURAL PRODUCTS IN RESEARCH AND	
THERAPY WITH PSYCHOACTIVE ETHNONOTANICALS	121
ETHICAL CONCERNS	123
Access, Costs, and Reciprocity	123
Sustainable Polypharmacology	126
FUTURE CHALLENGES	127
CONCLUSION	128
CONSENT FOR PUBLICATION	128
CONFLICT OF INTEREST	129
ACKNOWLEDGEMENTS	
REFERENCES	129
CHAPTER 4 NEUROPROTECTIVE EFFECTS OF POLYPHENOLS	146
Ali Imran, Javeria Maqbool, Azhar Rasul, Haseeb Anwar, Shoaib Ahmad Malik	170
Rabia Akram, Faiqa Sajid, Amna Rashid Tariq, Muhammad Umair Arshad and	
Ghulam Hussain	

INTRODUCTION	
CLASSIFICATION	
CHEMICAL CHARACTERISTICS	
SOURCES OF PHENOLIC COMPOUNDS	
BIOLOGICAL ACTIVITIES OF PHENOLIC COMPOUNDS	
Anti-Oxidative Activity	
Anti-inflammatory Activity	
Anti-hypertensive Activity	
Anti-Neurotoxicity Activity	
Autophagic Activity	
NEUROPROTECTIVE ROLE OF PCS	
Huntington's Disease	
Parkinson's Disease	
Multiple Sclerosis	
Alzheimer's Disease	
Amyotrophic Lateral Sclerosis	
Epilepsy	
Stroke	
CONCLUSION	
CONCLUSION	
CONSERVEROR FOR FOREIGN	
ACKNOWLEDGEMENTS	
ACKNOWLEDGEMENTS	
REFERENCES	
	TR OL TITLE
IAPTER 5 NEUROPROTECTION WITH THE FUNCTIONAL HERBS	
MIACEAE FAMILY	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE)	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE)	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present)	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS)	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background Neuroprotective Effects of P. frutescens	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background Neuroprotective Effects of P. frutescens SIDERITIS SCARDICA (S. SCARDICA)	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background Neuroprotective Effects of P. frutescens SIDERITIS SCARDICA (S. SCARDICA) Background	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background Neuroprotective Effects of P. frutescens SIDERITIS SCARDICA (S. SCARDICA) Background Neuroprotective Effects of S. scardica	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background Neuroprotective Effects of P. frutescens SIDERITIS SCARDICA (S. SCARDICA) Background Neuroprotective Effects of S. scardica OCIMUM SANCTUM (O. SANCTUM)	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background Neuroprotective Effects of P. frutescens SIDERITIS SCARDICA (S. SCARDICA) Background Neuroprotective Effects of S. scardica OCIMUM SANCTUM (O. SANCTUM) Background	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background Neuroprotective Effects of P. frutescens SIDERITIS SCARDICA (S. SCARDICA) Background Neuroprotective Effects of S. scardica OCIMUM SANCTUM (O. SANCTUM) Background Neuroprotective Effects of O. sanctum	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background Neuroprotective Effects of P. frutescens SIDERITIS SCARDICA (S. SCARDICA) Background Neuroprotective Effects of S. scardica OCIMUM SANCTUM (O. SANCTUM) Background Neuroprotective Effects of O. sanctum ORIGANUM SYRIACUM (O. SYRIACUM)	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background Neuroprotective Effects of P. frutescens SIDERITIS SCARDICA (S. SCARDICA) Background Neuroprotective Effects of S. scardica OCIMUM SANCTUM (O. SANCTUM) Background Neuroprotective Effects of O. sanctum ORIGANUM SYRIACUM (O. SYRIACUM) Background	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background Neuroprotective Effects of P. frutescens SIDERITIS SCARDICA (S. SCARDICA) Background Neuroprotective Effects of S. scardica OCIMUM SANCTUM (O. SANCTUM) Background Neuroprotective Effects of O. sanctum ORIGANUM SYRIACUM (O. SYRIACUM) Background Neuroprotective Effects of O. sanctum	
MIACEAE FAMILY Keng Yoon Yeong and Kar Wei Chin INTRODUCTION Background and Disease Pathogenesis Plants as Medicines Before Common Era-Common Era (6000 BCE- 650 CE) Middle Ages (500 CE-1500 CE) Modern era (1500 CE -present) Lamiaceae Plants Association Between Lamiaceae Plants and Neuroprotection PERILLA FRUTESCENS (P. FRUTESCENS) Background Neuroprotective Effects of P. frutescens SIDERITIS SCARDICA (S. SCARDICA) Background Neuroprotective Effects of S. scardica OCIMUM SANCTUM (O. SANCTUM) Background Neuroprotective Effects of O. sanctum ORIGANUM SYRIACUM (O. SYRIACUM) Background	

ORTHOSIPHON STAMINEUS (O. STAMINEUS+".0000	191
Background	
Neuroprotective Effect of O. stamineus	
STACHYS SIEBOLDII (S. SIEBOLDII)	
Background	
Neuroprotective Effects of Stachys sieboldii	
POGOSTEMON CABLIN (P. CABLIN)	
Background	
Neuroprotective Effects of P. cablin	195
PRUNELLA VULGARIS (P. VULGARIS)	196
Background	196
Neuroprotective Effects of P. vulgaris	197
CONCLUSION	
CONSENT FOR PUBLICATION	198
CONFLICT OF INTEREST	
ACKNOWLEDGEMENTS	199
REFERENCES	199
CHAPTER 6 COUMARIN DERIVATIVES AS POTENTIAL ANTI-INFLAMMATORY AGENTS FOR DRUG DEVELOPMENT	213
Abdul Jalil Shah, Reyaz Hassan Mir, Roohi Mohi-ud-din, Saba Sabreen, Nazia	
Banday, Mudasir Maqbool Bhat and Mubashir Hussain Masoodi	
INTRODUCTION	213
COUMARINS	
Classification of Coumarins	
NATURALLY OCCURRING COUMARINS	
STRUCTURE-ACTIVITY RELATIONSHIP OF COUMARINS	
VARIOUS SYNTHETICALLY DESIGNED COUMARIN DERIVATIVES	221
Derivatives of Oxadiazole and Thiazole	221
Derivatives of Mannich Base and Schiff Base	222
Derivatives of Benzofuran	223
Alkyl Derivatives	223
Derivatives of Pyrazole and Isoxazole	227
Other Derivatives	228
CONCLUSION	231
CONSENT FOR PUBLICATION	231
CONFLICT OF INTEREST	231
ACKNOWLEDGEMENTS	231
REFERENCES	231
CHAPTER 7 RECENT PROGRESS IN THE SYNTHESIS AND BIOLOGICAL ACTIVITY	
CHROMENE AND ITS DERIVATIVES	239
Hossein Eshghi, Fatemeh Pirani and Mahsa Khoshnevis INTRODUCTION	
SYNTHESIS OF CHROMENE DERIVATIVES	
Synthesis of 2H-Chromenes	
Synthesis of 4H-Chromenes	
Synthesis of Benzochromenes	
Synthesis of Benzopyrans	
Synthesis of Fused-Chromenes	
BIOLOGICAL ACTIVITY OF CHROMENES	
Anti-Cancer Activity	253

Anti-Inflammatory Activity	258
Anti-Oxidant Activity	261
Antimicrobial Activity	266
SEVERAL METHODS AND STRATEGIES FOR SYNTHESIZING CHROMENE	
DERIVATIVES	267
Green Synthesis of Chromenes	268
Multicomponent Reaction for the Synthesis of Chromenes	270
Solvent Free Synthesis of Chromenes	272
Catalytic Synthesis of Chromenes	274
Microwave-Assisted Synthesis of Chromenes	276
CONCLUDING REMARKS	278
CONSENT FOR PUBLICATION	278
CONFLICT OF INTEREST	278
ACKNOWLEDGEMENTS	278
REFERENCES	278
SUBJECT INDEX	305

PREFACE

Frontiers in Natural Product Chemistry presents recent advances in the chemistry and biochemistry of naturally occurring compounds. It covers a range of topics, including important researches on natural substances. The book is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information on bioactive natural products.

The chapters in this volume are written by eminent authorities in the field. Bose *et al.*, in chapter 1 of the volume, explain recent developments regarding antiviral agents from seaweeds and seagrass. Singh *et al.*, in chapter 2, present a comprehensive review of various quinolizidine and *bis*-1-oxaquinolizidine alkaloids isolated from marine organisms, presenting their chemical structures and reported biological properties. Ona and Bouso, in chapter 3 of the book, review the use of natural product mixtures instead of isolated compounds thereby combining two recent paradigms: psychedelic assisted therapy on the one side and polypharmacology on the other. Hussain *et al.*, in chapter 4 give a brief overview of the physiological activities of phenolic compounds along with their potential neuroprotective effects . Yeong and Chin discuss the neuroprotective effects and bioactive constituents of common herbs from the Lamiaceae family in chapter 5 of the book. Masoodi *et al.* review the coumarin derivatives as potential anti-inflammatory agents for drug development in chapter 6. In the last chapter of the book, *Eshghi et al.* discuss the recent progress in the synthesis and biological activity of chromene and its derivatives.

I hope that the readers will find these reviews valuable and thought-provoking so that they may trigger further research in the quest for new and novel therapies against various diseases. I am grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications), Mr. Obaid Sadiq (In-charge Books Department), and Miss Asma Ahmed (Senior Manager Publications) at Bentham Science Publishers.

Atta-ur-Rahman, FRS Kings College University of Cambridge Cambridge UK

List of Contributors

Abdul Jalil Shah	Pharmaceutical Chemistry Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar-190006, Kashmir, India
Ali Imran	Institute of Home and Food Sciences, Government College University, Faisalabad, Pakistan
Amna Rashid Tariq	Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan
Archana Singh	Bioorganic Chemistry Laboratory, CSIR-National Institute of Oceanography, Dona Paula-403004, Goa, India National Centre for Polar and Ocean Research, Ministry of Earth Sciences, Vasco da Gama-403802, Goa, India School of Chemical Sciences, Goa University, Taligao-403001, India
Azhar Rasul	Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Pakistan
Faiqa Sajid	Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, Pakistan
Fatemeh Pirani	Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 91775-1436, Iran
Genís Ona	ICEERS - International Center for Ethnobotanical Education, Research and Service, Barcelona, Spain Universitat Rovira i Virgili, Medical Anthropology Research Center (MARC), Department of Anthropology, Philosophy and Social Work, Tarragona, Spain
Ghulam Hussain	Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, Pakistan
Haseeb Anwar	Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, Pakistan
Hossein Eshghi	Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 91775-1436, Iran
José Carlos Bouso	ICEERS - International Center for Ethnobotanical Education, Research and Service, Barcelona, Spain Universitat Rovira i Virgili, Medical Anthropology Research Center (MARC), Department of Anthropology, Philosophy and Social Work, Tarragona, Spain
Javeria Maqbool	Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, Pakistan
Kar Wei Chin	School of Science, Monash University Malaysia, Bandar Sunway, Malaysia
Keisham S. Singh	Bioorganic Chemistry Laboratory, CSIR-National Institute of Oceanography, Dona Paula-403004, Goa, India
Keng Yoon Yeong	School of Science, Monash University Malaysia, Bandar Sunway, Malaysia

Mahsa Khoshnevis	Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 91775-1436, Iran
Mubashir Hussain Masoodi	Pharmaceutical Chemistry Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar-190006, Kashmir, India
Mudasir Maqbool Bhat	Pharmacy Practice Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar, 190006, Kashmir, India
Muhammad Umair Arshad	Institute of Home and Food Sciences, Government College University, Faisalabad, Pakistan
Nazia Banday	Pharmacognosy Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar, 190006, Kashmir, India
Rabia Akram	Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, Pakistan
Reyaz Hassan Mir	Pharmaceutical Chemistry Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar-190006, Kashmir, India
Roohi Mohi-ud-din	Pharmacognosy Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar, 190006, Kashmir, India
Saba Sabreen	Pharmaceutical Chemistry Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar-190006, Kashmir, India
Sabyasachi Banerjee	Gupta College of Technological Sciences, G. T. Road, Asansol 713301, India
Sankhadip Bose	Bengal School of Technology, Sugandha, Chuchura, Hooghly - 712102, India
Satarupa Acharjee	NSHM Knowledge Campus, Kolkata – Group of Institutions, 124, B.L. Saha Road, Kolkata 700053, India
Shoaib Ahmad Malik	Department of Biochemistry, Sargodha Medical College, University of Sargodha, Sargodha, Pakistan
Supriya Tilvi	Bioorganic Chemistry Laboratory, CSIR-National Institute of Oceanography, Dona Paula-403004, Goa, India

Chemistry, Antiviral Properties and Clinical Relevance of Marine Macroalgae and Seagrass

Satarupa Acharjee¹, Sabyasachi Banerjee² and Sankhadip Bose^{3,*}

¹ NSHM Knowledge Campus, Kolkata – Group of Institutions, 124, B.L. Saha Road, Kolkata 700053, India

² Gupta College of Technological Sciences, G. T. Road, Asansol 713301, India

³ Bengal School of Technology, Sugandha, Chuchura, Hooghly – 712102, India

Abstract:

Background

Marine organisms are always considered as one of the richest sources of natural products. Historically, they are being used as medicines in diverse ailments. In recent years, researchers have reported several primary and secondary metabolites in marine organisms (few examples are macroalgae, sponges, seagrasses, bacteria, microalgae), which serve in numerous disorders, of which 20–25% have shown antiviral, antimicrobial, antifungal, anticancer or anti-inflammatory properties. According to the global pharmaceutical website, there are a total of nine approved pharmaceuticals from a marine source, and apart from this, thirty-one other compounds are currently in a clinical trial.

Objective

Discovery of potent antiviral drugs is required currently to mitigate life-threatening viruses. Considerable research exploring the bioactivity of marine macroalgae has been documented, highlighting the immense biochemical diversity of its primary and secondary metabolites with a novel mechanism of action, making them perfect sources for novel antiviral bioactive compounds of pharmaceutical interest.

Methods

Databases utilizing bibliographic databanks, such as PubMed, SpringerLink, Elsevier journal, Science Direct, Scopus databases, and Google search were surveyed using keywords anti-viral, seaweeds, antiviral drugs, seagrass, polyphenols, pharmacology, clinical trials.

Results

Marine phytoplanktons are found to be the major source of several key medicinal agents (polyphenols, phenolic compounds), which are largely obtained from seaweeds

Atta-ur-Rahman, *FRS* (Ed.) All rights reserved-© 2021 Bentham Science Publishers

^{*} Corresponding author Sankhadip Bose: Bengal School of Technology, Sugandha, Chuchura, Hooghly – 712102, India; Tel: +91 9932641201; E-mail: sankha.bose@gmail.com

2 Frontiers in Natural Product Chemistry, Vol. 8

Acharjee et al.

and seagrasses and have shown promising antiviral activity in cell culture studies. This review explains recent developments regarding antiviral agents from seaweeds and seagrass.

Keywords: Antiviral Drugs, Polyphenols, Seagrass, Seaweeds.

INTRODUCTION

Since the last 50 years, a huge number of novel compounds and their metabolites, with different biological properties ranging from anticancer to antiviral, have been procured from diverse marine organisms, some of which are presently in use [1]. Extreme rivalry, feeding pressure coupled with non-static marine environmental conditions lead to the generation of compounds with chemical and structural characteristics that are not commonly found in terrestrial plants [2]. It's this rare feature that renders the marine ecosystem a prolific storehouse of potential bioactive natural products to combat major diseases. Marine natural products are majorly secondary metabolites having no primary function related to the development, growth, or propagation of a species. Till 2008, around 68% of antiinfective agents (including antibacterial, antiviral, antiparasitic, and antifungal compounds) [3] were naturally derived. Over the last decades, there has been a surge in the demand for novel antivirals as different forms of infectious diseases caused by emerging or re-emerging viruses continue to pose a significant threat to humanity. In the light of the current pandemic situation due to the SARS-CoV2 virus, the market for antivirals is assumed to rise from \$52.2 billion in 2019 to about \$59.9 billion in 2020 [4], due to increasing demands for antiretroviral drugs utilized in the treatment of covid-19 patients along with potential antivirals, which could mitigate infection.

According to the global marine pharmaceutical website, there are currently 9 approved marine-derived pharmaceuticals [2] and an additional 31 compounds either in Phase I, II, and III of clinical pharmaceutical development [5]. Amongst them, Carragelose[®] and Vira-A[®] are antivirals approved for common cold/influenza-like infections and keratoconjunctivitis/keratitis due to herpes simplex virus (HSV), respectively. Despite a huge repertoire of antivirals approved for clinical use, insufficient drug efficacy, drug toxicity, along with the high cost of current antiviral drugs pose a challenge to the treatment.

Given the fact that there is interspecies variability in the life cycle of viruses, the six basic stages, *i.e.*, attachment, penetration (also called virus entry), uncoating, replication, assembly, and release, are found to be the targets for antivirals [6]. Following the stage of viral entry, transcription and replication of virus-specific ribonucleic acids (RNAs) are carried out by a viral polymerase complex. Unlike

the polymerases of eukaryotic cells, viral polymerase lacks an error correction mechanism. Therefore, the frequency of mutations of the viral genome is 10^4 to 10^6 nucleotides per replication cycle according to various estimates. This is several orders of magnitude higher than the rate of mutation in bacteria and eukaryotes. As a result of the rapid rate of mutations, the virus escapes the immune response of the host. Thus, given the creation of an immune layer in the population due to vaccination and natural occurrence, annual epidemics occur. In addition, drug-resistant viral strains have grown as a result of the use of antiviral drugs, decrementing their efficacy [7].

Bioprospecting efforts since the last 40 years have led to over 20,000 compounds of marine origin. Based on the discovery of drugs from the natural origin such as, lovastatin and paclitaxel, it is speculated that the marine environment might yield more potent antiviral candidates with higher efficiency, better selectivity and lesser chances of resistance development. This situation warrants novel lead molecules from untapped natural resources to be investigated for the development of alternative therapy as nature generally create more refined and improved systems with a complex mode of action.

REASON OF SPECIAL INTEREST IN MACROALGAE AND SEAGRASS AS NOVEL ANTIVIRALS

Marine sponges, corals, and microorganisms form 70% of marine metabolites, whereas molluscs, ascidians, and algae metabolites are just a small proportion [2]. Of late, marine phytoplanktons, including macroalgae and seagrass, have attracted considerable attention due to promising antiviral activity. *Chlorella vulgaris*, an aquatic microalga, was first reported to have antibacterial activity [8], followed by antimicrobial properties of macroalgae/seaweed extracts in the coming two decades [9]. Micro and macroalgae were one of the primary sources of natural components exhibiting *in vitro* anti-human immunodeficiency virus (anti-HIV) activity [10]. Halitunal, a novel diterpenealdehyde isolated from marine algae *Halimeda tuna* showed *in vitro* antiviral effect against murine coronavirus [11], while *in vivo* protection against *Semeliki forest* virus was exhibited by sphingosine isolated by Indian green algae *Ulva fasciata* [12]. Sulphated flavones Thalassoilins A, B and C, isolated from sea grass *Thalassia testudinum* [13], were found to restrain HIV enzyme integrase *via* binding to the catalytic domain of HIV integrase.

Marine polysaccharides, as biological macromolecule, have been discovered to be of utmost significance among the enormous amount of marine extracts. Although they extensively exist in marine biodiversity, including animals [14, 15], plants and microorganisms [16, 17], seaweeds (macroalgae) have been reported to be the

Quinolizidine Alkaloids from Marine Organisms: A Perspective on Chemical, Bioactivity and Synthesis

Archana Singh^{1,2,3}, Supriya Tilvi¹ and Keisham S. Singh^{1,*}

¹ Bioorganic Chemistry Laboratory, CSIR-National Institute of Oceanography, Dona Paula-403004, Goa, India

² National Centre for Polar and Ocean Research, Ministry of Earth Sciences, Vasco da Gama-403802, Goa, India

³ School of Chemical Sciences, Goa University, Taligao-403001, India

Abstract: Marine organisms produce numerous secondary metabolites that exhibit a wide range of biological activities, which have applications in pharmaceutical research. Numerous secondary metabolites have been discovered from various marine organisms and studied for their chemical and biological properties. Among the secondary metabolites of marine organisms, alkaloids constitute a versatile group of bioactive natural products with promising bio-activities. Several alkaloids, such as pyridoacridines, pyrroles, bisindole, isoquinolines, quinolizidines and bromotyrosines, etc., to name a few, have been isolated from marine organisms. The chemical diversity and bio-activities of marine alkaloids are reported in several research and review articles. Quinolizidine alkaloids (QAs) are a group of compounds that possess either a quinolizidine ring or its derivatives. They are isolated from terrestrial plants, animals and also from numerous marine organisms, such as sponges, tunicates, fungus, etc. Biological activities exhibited by QAs include ichthyotoxicity, chemical defense, antimicrobial, antiviral, and inhibition of nicotinic acetylcholine receptors. In the past years, a few scattered reviews appeared on the isolation of QAs from natural sources, mostly from terrestrial sources, but the reports skipped several QAs of marine origin. This chapter presents a comprehensive review of various quinolizidine and bis-1-oxaquinolizidine alkaloids isolated from marine organisms, detailing their chemical structures and reported biological properties. Further, the chapter highlighted synthesis of some marine-derived QAs, namely, petrosins, xestospongins, clavepictines, pictamine, citrinadins A and B.

Keywords: 1-Oxa-Bisquinolizidine, Marine Organisms, Pictamine Alkaloid, Quinolizidine Alkaloids, Sonogoshira Coupling, Sponges, Synthesis, Tunicates.

Atta-ur-Rahman, *FRS* (Ed.) All rights reserved-© 2021 Bentham Science Publishers

^{*} Corresponding author Keisham S. Singh: Bioorganic Chemistry Laboratory, CSIR-National Institute of Oceanography, Dona Paula-403004, Goa, India; Tel.: +91-0832 24503 92; Fax: +91 0832 2450 607; E-mails: keisham@nio.org & keisham.sarjit@gmail.com

INTRODUCTION

Marine life represents highly prolific and rich biodiversity on the earth. It not only supports the livelihood of millions of people but also gives pharmacologically important bioactive compounds. Indeed, several biologically active compounds have been discovered from the marine environment, of which many of them are under clinical and preclinical trials, while a few candidates have already entered the market [1]. Numerous bioactive compounds have been isolated from marine organisms, which include alkaloids, terpenoids, sterols, pyrones and peptides, etc., to name a few. Alkaloids represent one of the most important bioactive compounds isolated from marine organisms [2]. The chemical and biological activities of alkaloids isolated from sponges [3], ascidians [4] and bacteria [5] have been well documented. Further, over the past years, alkaloids derived from marine organisms viz. pyrrole [6, 7], bromotyrosine [8], indole [9], pyridine [10], and pyridoacridine [11] have also been presented in several research and review articles. However, a review dedicated to marine-derived quinolizidine alkaloids, which are known for their diverse bioactivities, is so far lacking, although a few scattered reports are available in the literature [3, 4, 12].

QAs are a group of alkaloid family that contains a quinolizidine ring. Most of the QAs possess diverse biological activities, and they are known from both terrestrial plants as well as marine organisms [13 - 15]. They comprised more than 2% of all the alkaloids isolated from terrestrial plants. QAs can be grouped into eight structural types, namely, lupinine (1), sparteine (2), lupanine (3), anagyrine (4), tetrahydrorhobifoline (5), cytosine (6), matrine (7) and multiflorine (8) (Fig. 1) [16]. In the marine environment, QAs have been isolated from various organisms, primarily from sponges, and a few are isolated from ascidian and fungi. QAs isolated from the marine environment are mostly lupinine type. Biological properties of marine-derived QAs include vasodilative [17], ichthyotoxicity [18], anticancer [19], anti-HIV [20], antimicrobial [21], cytotoxicity [22] and antimalarial (Table 1) [23].

Compounds	Source	Bioactivity	References
Petrosin (9)	Sponge: Petrosia seriata, Oceanapiasp., Petrosia similis	Ichthyotoxicity, antimicrobial, anti-HIV	[18, 20, 21, 25]
Petrosin A (10)	Petrosia similis	Anti-HIV	[20]
Araguspongine A (26)	Xestospongia sp.	NO inhibition	[33]

Table 1. Selected quinolizidine alkaloids derived from marine organisms with their bioactivity.

Marine Organisms

Frontiers in Natural Product Chemistry, Vol. 8 47

Compounds	Source	Bioactivity	References
Araguspongines N-P (37-39) Araguspongins K (30) & L(31) Aragupetrosin A (24)	Xestospongia muta Xestospongia exigua Xestospongia sp.	NO inhibition Antimalarial Vasodilative	[17, 23, 41]
Xestospongin C (14)	Oceanapia sp., Xestospongia exigua	Antimicrobial	[21, 27]
Xestospongin D (15)	Oceanapia sp., Xestospongia exigua, Niphates sp.,	Antimicrobial, anticancer, vasodilative	[21, 27, 28]
Araguspongine C (17)	Xestospongia sp., Xestospongia exigua, Xestospongia muta	Anticancer, cytotoxic, vasodilative, antimalarial, antituberculosis, antifungal, antifouling	[19, 22, 23, 29, 36, 37, 41]
Araguspongines M (32), B (13) and D (18)	Neopetrosia exigua	Cytotoxic	[22]
Demethylxestospongin B (25)	Xestospongia muta, Xestospongia sp.	Cytotoxic antifungal activity	[34, 39]
Clavepictine A (43) and clavepictine B (44)	Clauelina picta (Ascidian)	Antitumor, antimicrobial	[45, 46]
citrinadin A (46)	Actinotrichia fragilis, Penicillium citrinum	Cytotoxicity	[48, 49]

This chapter presents a comprehensive review of the various quinolizidine and bis-1-oxaquinolizidine alkaloids isolated from marine organisms, namely, sponges, tunicates, fungus, *etc.*, detailing their chemical structures and reported biological properties. Further, the chapter describes the total synthesis of marine-derived QAs *viz.*, petrosins, xestospongins, clavepictines, pictamine, and citrinadins A and B.




Fig. (1). Structural types of quinolizidine alkaloids.

Towards the Use of Whole Natural Products in Psychedelic Research and Therapy: Synergy, Multi-Target Profiles, and Beyond

Genís Ona^{1,2} and José Carlos Bouso^{1,2,*}

¹ ICEERS - International Center for Ethnobotanical Education, Research and Service, Barcelona, Spain

² Universitat Rovira i Virgili, Medical Anthropology Research Center (MARC), Department of Anthropology, Philosophy and Social Work, Tarragona, Spain

Abstract: Interest in psychoactive ethnobotanicals such as ayahuasca or *Psilocybe* mushrooms for clinical uses has increased over the last two decades. While clinical and experimental approaches have focused on using isolated compounds of interest (such as psilocybin), an emerging trend in drug discovery involves a more comprehensive approach. The polypharmacology paradigm, as it has been named, suggests that promiscuous drugs could be safer and more effective than highly selective ones. This is especially relevant with regards to complex diseases, like most mental health problems and neurodegenerative diseases, and for natural products, including psychoactive ethnobotanicals. Natural products not only show a multi-target profile, but they also contain several compounds capable of interacting with one another and producing synergistic effects. In this chapter, the use of whole natural products instead of isolated compounds is suggested in support of combining two recent paradigms: psychedelic-assisted therapy on the one side and polypharmacology on the other.

Keywords: Natural products, Polypharmacology, Psychedelics, Synergy.

INTRODUCTION

Cultures around the world have long used psychoactive ethnobotanicals (PE) like *Tabernanthe iboga* and *Psilocybe cubensis*. Lesser-known or at least less-rituallyused PE in Western societies includes *Amanita muscaria* and some *Datura* species [1]. Despite this long-established tradition, it has only been in recent decades that researchers decided to elucidate the complex and unique effects

Atta-ur-Rahman, *FRS* (Ed.) All rights reserved-© 2021 Bentham Science Publishers

^{*} Corresponding author José Carlos Bouso: International Center for Ethnobotanical Education, Research and Service, Barcelona, Spain; and Universitat Rovira i Virgili, Medical Anthropology Research Center (MARC), Department of Anthropology, Philosophy and Social Work, Tarragona, Spain; Tel: 93 188 20 99; E-mail: jcbouso@iceers.org

100 Frontiers in Natural Product Chemistry, Vol. 8

produced by PE. These plants and fungi have challenged anthropologists, psychologists, pharmacologists, health professionals, and anyone else who approached them. Beyond the complexities easily found among natural products, PE are challenging because of their ability to induce altered states of consciousness that dramatically change how we see both the external and internal worlds. Both the pharmacological and the psychological effects of PE are pushing the limits of our knowledge, challenging us to develop new understandings that will eventually lead to innovative and effective ways to deal with physical and mental disorders.

One of these new understandings concerns how we use drugs for the treatment of diseases or their symptoms. The classical posology, in which one should take a pill every eight hours and expect symptom-relief effects, might be replaced by a limited number of sessions within a psychotherapeutic setting in which you take a PE, and your therapist guides you through a transformative psychological journey. However, another new understanding, the one this chapter focuses on, concerns how we develop new drugs. The approach on which pharmacology has been based during the last century consists of isolating active principles found in natural products and developing medications that are as selective as possible. This idea was elegantly suggested by Paul Ehrlich (1854-1915), Nobel Prize laureate, at the end of the 19th century, although similar ideas were proposed at the end of the 18th century by E.A. Nicolai. According to Ehrlich, the optimal agents for the treatment of infections (which he termed "magic bullets") would be the ones with a high affinity for the pathogen and low toxicity for the patient ("high parasitotropism with low organotropism," in his words) [2]. Notably, Ehrlich successfully developed a "magic bullet," arsphenamine, which was the first human-produced antibiotic [2, 3]. Although this approach was especially valid in the case of infections, it was also used as a model for general drug development until very recently, continuing the assumption that a selective ligand that does not interact with a high number of biological targets is always preferable. This paradigm's zenith was reached following the completion of the human genomesequencing project in 2000 [4]. After 10 years of international collaboration, the human genome was finally revealed, further encouraging the identification of disease-causing genes for subsequent molecular interventions [5]. However, while Ehrlich's "magic bullets" were effective only when dealing with infections, genetically-developed "magic bullets" are effective in the few cases where diseases are caused by single genes. Unfortunately, the etiology of most of the central nervous system (CNS) disorders is unknown, often polygenic, and epigenetically modulated by several factors [6 - 9]. Moreover, the paradigm that conceives of diseases as a kind of house of cards, where if you take out one or two cards from the base, the entire structure will collapse, is progressively being substituted by a model in which diseases are considered systems sustained by large and complex biological networks [10]. Natural products, including PE, offer us complex tools capable of dealing with those networks. Thus, in recent years, the use of multi-target ligands and whole natural products has been observed as potentially being more advantageous than highly selective ligands. This has led to a paradigm shift in drug discovery towards the polypharmacology approach that embraces the use of multi-target drugs. We believe that these advances should be applied to the clinical use of PE, as most of them are of a natural origin. This chapter provides a fertile background for effectively connecting psychedelic research with polypharmacology, two emerging, innovative, and promising paradigms.

In order to effectively use natural products in general and PE specifically, it is necessary to understand them and their mechanisms of action. Fortunately, major developments have recently occurred in the field of natural products research. This chapter's following sections will present the current knowledge on the topic, first introducing the concept of synergy and other interactions between the compounds in natural products; then, recent advances obtained in the field of psychedelic medicine focusing on PE *P. cubensis*, *T. iboga*, and ayahuasca will be outlined; reasons for using whole products rather than isolated compounds (*e.g.*, psilocybin in the case of *P. cubensis*) will be discussed; ethical concerns regarding sustainability and traditional knowledge will be considered; and lastly, future challenges and recommendations will briefly be suggested.

INTERACTIONS BETWEEN COMPOUNDS IN NATURAL PRODUCTS AND THEIR MULTI-TARGET EFFECTS

Plants have developed the ability to interact with their surroundings in various ways, either communicating with other plants [11] or attracting/repelling insects and herbivores [12, 13]. The production of flowers exemplifies the extent to which plants interact with other beings, as flowers were specifically developed when plant reproduction started to be in collaboration with insects, and therefore they had to attract them using different stimuli (colours, odours, nectar, *etc.*).

Plants' defence strategies have attracted remarkable attention, and there are currently several hypotheses regarding why they exist [14]. The defence process is highly complex and involves both direct and indirect actions. Chemicals produced by plants play a vital role in those actions. In order to carry out not only defence mechanisms but also several other complex processes, plants have developed different classes of chemicals (*e.g.*, flavonoids, alkaloids, terpenoids, and fatty acids, among others). Some of them are known as secondary metabolites, which is to say, compounds not directly linked to the basic processes of the plant (feeding, growth) but associated with the enhancement of survival. Among the direct

CHAPTER 4

Neuroprotective Effects of Polyphenols

Ali Imran³, Javeria Maqbool¹, Azhar Rasul², Haseeb Anwar¹, Shoaib Ahmad Malik⁴, Rabia Akram¹, Faiqa Sajid¹, Amna Rashid Tariq⁵, Muhammad Umair Arshad³ and Ghulam Hussain^{1,*}

¹ Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, Pakistan

² Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Pakistan

³ Institute of Home and Food Sciences, Government College University, Faisalabad, Pakistan

⁴ Department of Biochemistry, Sargodha Medical College, University of Sargodha, Sargodha, Pakistan

⁵ Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan

Abstract: Phenolic compounds, the bioactive phytochemicals, are abundantly found in a huge variety of food items, including fruits, vegetables, cereals, legumes, and herbs. Phenolic compounds are often called phenols, phenolics, and polyphenols. They are secondary metabolites of plants and are considered an integral part of both animal and human diet. Natural phenolic compounds have acquired increasing attention in the last few years because of their countless health-related therapeutic interventions. Biological activities of phenolic compounds include anti-oxidative, anti-inflammatory, antiallergic, and anti-hypertensive are found to play their role in neuroprotection. All of these above mentioned properties of different phenolic compounds play a critical and central role in preventing the progression of neurodegenerative, neurological disorders and brain injuries. A list of phenolic compounds including resveratrol, quercetin, rutin, curcumin, baiclein, luteolin, and (-) Epigallocatechin-3-gallateon have been discussed in detail in the context of their neuroprotective action. The present chapter describes a brief and comprehensive overview of the physiological activities of phenolic compounds along with their potential neuroprotective approach.

Keywords: Antioxidants, Cognitive Functions, Neurodegenerative Diseases, Neuronal Survival, Neuroprotection, Phenolic Compounds.

^{*} **Corresponding author Ghulam Hussain:** Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, Pakistan; Tel: 03006654101; E-mails: ghulamhussain@gcuf.edu.pk & gh_azer@hotmail.com

INTRODUCTION

Polyphenol compounds, sometimes called phenolics and phenols, are an extensive class of chemical compounds containing a hydroxyl group (-OH). Phenolic compounds are the secondary metabolites which are classified based on the number of phenol units present in one molecule [1, 2]. Phenolic compounds (PCs) are not only produced by various species of microorganisms and plants but are also synthesized industrially [3]. These substances contain a variety of compounds such as complex and simple flavonoids, phenolic acids, coumarins, phenylpropanoids, stilbenoids, phenols, lignans, and xanthones [4]. These compounds are potentially involved in maintaining human health *via* acting as anti-inflammatory, anti-aging, anti-proliferative and anti-oxidative agents [5]. Several studies reported that phenols are beneficial in some neuropsychiatric disorders, neurodegenerative diseases, and brain injuries [6]. In this regard, the potential therapeutic and neuroprotective approaches of different phenolic compounds are illustrated in the next sections of this chapter.

CLASSIFICATION

Phenolic compounds are classified into different classes based on the number and location of the hydroxyl group. Among the natural phenols, the most important and vast class is flavonoids, which contain flavones, flavanones, isoflavonoids and anthocyanins. However, a detailed classification of phenolic compounds is well presented in Fig. (1) below.




Fig. (1). Classification of phenolic compounds and their examples.

CHEMICAL CHARACTERISTICS

Principally, phenolic compounds as a diverse group of phytochemicals are involved in the modulation of various physiological processes of the living system [7, 8]. Because of the chemical characteristics of these compounds, it is worthy to state that these compounds exist in both volatile and soluble forms. However, the majority of these compounds are soluble. The structures of these phenolic compounds with their major classes are illustrated below in Fig. (2).




Fig. (2). Structures of main classes of phenolic compounds.

Neuroprotection with the Functional Herbs from the Lamiaceae Family

Keng Yoon Yeong^{1,*} and Kar Wei Chin¹

¹ School of Science, Monash University Malaysia, Bandar Sunway, Malaysia

Abstract: The growth of the average lifespan of the global population is accompanied by a progressive increase in the prevalence of neurodegenerative disease (NDD). Common NDDs such as Alzheimer's, Parkinson's, Huntington's diseases, and others are known to be strongly related to aging. The prevalence of NDD is expected to increase steeply with the increment in life expectancy. The currently available therapeutic interventions are mainly symptomatic, and most have failed to reverse or slow down the disease progression. Hence, new treatments and preventive measures are urgently needed. Plants from the Lamiaceae family have reported several neuroprotective effects attributed to the abundance of secondary metabolites that could target multiple pathways of the cellular death mechanism. Owing to the multifactorial nature of NDDs, the abundance of secondary metabolites in plants has attracted the attention of researchersto the neuroprotective potentials of natural products. The neuroprotective effects and bioactive constituents of common herbs such as Perilla frutescens (Perilla), Sideritis scardica (Ironwort), Ocimum sanctum (Holy basil), Origanum syriacum (Lebanese oregano), Satureja bachtiarica (Bakhtiari savory), Orthosiphon stamineus (Cat whisker), Prunella vulgaris (Prunella), Pogostemon cablin (Patchouli) and Stachys sieboldii (Japanese artichoke) from the Lamiaceae family are discussed in this chapter. The neuroprotective property of these herbs relied on their ability to target the underlying mechanisms of neuronal cell death, such as aberrant protein aggregation, excessive oxidative stress, neurotransmission system dysfunction, neuroinflammation, and others. The multi-targeting ability of these plants is attributed to their complex chemical compositions with different bioactive compounds. Thus, the incorporation of these plants and herbs into the management of NDD should be further explored. Their role as dietary supplements to preserve the function of the nervous system is also strongly advocate.

Keywords: Lamiaceae, Neurodegenerative disease, Neuroprotective, Ocimum sanctum, Origanum syriacum, Orthosiphon stamineus, Perilla frutescens, Pogostemon cablin, Satureja bachtiarica, Sideritis scardica, Stachys sieboldii.

Atta-ur-Rahman, *FRS* (Ed.) All rights reserved-© 2021 Bentham Science Publishers

^{*} Corresponding author Keng Yoon Yeong: School of Science, Monash University Malaysia, Selangor, Malaysia; E-mail: yeong.kengyoon@monash.edu

INTRODUCTION

Background and Disease Pathogenesis

The nervous system is one of the most crucial systems in humans as it is responsible for the coordination and regulation of communication and process within the human body to maintain homeostasis and adaptation to the continually changing environment. Neurodegenerative disease (NDD) represents a group of disorders characterised by the irreversible loss of neurons and functions of the nervous system. The most common NDDs are Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease (HD). Patients afflicted with NDD usually suffer from a spectrum of disabilities such as cognitive and behavioural changes, mental disorders, and loss of motor control. Despite different clinical manifestations, the majority of the NDDs shared mutual pathogenesis of cell death. Established cell death pathogenesis includes the accumulation of aberrant protein, oxidative stress, neuroinflammation, excitotoxicity, synaptic dysfunction, neurotrophic factors deficiency, cellular protein degradation system dysfunction, and cellular apoptosis Interrelation of these activities are shown in Fig. (1).




Fig. (1). An overview of the causes of neuronal death.

Lamiaceae Family

As the global population starts to age, the incidence rate of NDDs is expected to rise exponentially, as the majority of them are classified as age-associated disorders. According to the World Alzheimer Report 2018, the number of people with dementia worldwide is likely to increase to 152 million by 2050 [1]. The prevalence of AD, the most frequently diagnosed NDD, increases exponentially above 65 years of age. In addition, the associated costs of care are expected to exceed over 1 trillion USD. This will impose a massive burden on the individual. society, and economy of a country. Unfortunately, most if not all of the current NDD treatments are mainly symptomatic treatments, and the efficacy is rather short-term with associated side effects. The low efficacy of most current therapies has led to an interest in finding alternative options to treat NDDs. Nevertheless, the complexity of NDDs makes it very difficult to pinpoint the exact cause of these disorders. Several hypotheses have been put forward over the years. First of all, the most common pathogenic factor of cellular death is the accumulation of aberrant proteins or commonly known as proteinopathies. For example, the deposition of amyloid-beta (A β) peptide and hyperphosphorylated tau (τ) protein in the form of neurofibrillary tangles in AD, aggregation of alpha-synuclein (α synuclein) proteins in the form of Lewy bodies in PD and Huntingtin proteins in HD [2]. These proteins could impair the structure of neuronal cells in the brain by forming calcium ion (Ca²⁺)-permeable pores on the plasma membrane leading to dysregulation of calcium ion homeostasis (excitotoxicity) and disrupting cellular signalling pathways leads to detrimental effects on the brain [3]. Under normal conditions, the protein aggregates are removed by the intracellular ubiquitinproteasome-autophagy system in order to restore protein dynamics. However, impairment of this system is found in many NDDs [4]. As a consequence, the misfolded protein accumulates and elicits toxic effects on the neuronal cells. In addition, the involvement of neuroinflammatory cascade was also a common feature of NDDs [5]. Neuroinflammation can either protect the brain from injury or infection by initiating tissue repair and removing cellular debris or amplify the damaging effect of the insult. The imbalance between pro-and anti-inflammatory pathways is associated with the persistent inflammatory response in the aging brain or diseased brain [6]. Pro-inflammatory cytokines such as interleukin (IL)-1 β and tumour necrosis factor (TNF)- α produced by activated microglial are essential in the modulation of inflammatory response to remove invaders or harmful substances. The injurious manner of inflammation is partially attributed to the secondary consequences originating from the pro-inflammatory cytokine in non-resolving inflammations. For instance, IL-1ß and IL-6 were reported to promote iron accumulation through alteration in iron transporter expression within the neuronal cell [7]. The altered iron homeostatic balance then leads to subsequent events such as reactive oxygen species (ROS) production, impaired mitochondrial functions, and increased pro-inflammatory activity [8]. The

Coumarin Derivatives as Potential Antiinflammatory Agents for Drug Development

Abdul Jalil Shah^{1,#}, Reyaz Hassan Mir^{1,#}, Roohi Mohi-ud-din^{2,*}, Saba Sabreen¹, Nazia Banday², Mudasir Maqbool Bhat³ and Mubashir Hussain Masoodi^{1,*}

¹ Pharmaceutical Chemistry Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar-190006, Kashmir, India

² Pharmacognosy Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar, 190006, Kashmir, India

³ Pharmacy Practice Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar, 190006, Kashmir, India

Abstract: The search for anti-inflammatory drugs is still challenging, even though recent advances in modern medicine have provided some relief. Coumarins, well known secondary metabolites widely distributed in plant kingdom, have successfully documented their candidature in the development of anti-inflammatory agents. Natural coumarins, including esculetin, umbelliferone, scopoletin and marmin showed potent anti-inflammatory activity through various targets, including COX-2, LOX, iNOS TNF- α , TXB2. Over the past decade, various synthetic modifications have been carried out on the scaffold of these natural products. The current review focuses on various synthetic and semi-synthetic modifications carried out on the coumarin nucleus with a primary focus on the evaluation of anti-inflammatory activity along with structure-activity relationship study.

Keywords: Anti-Inflammatory agents, Cox-2, Natural Coumarins, SAR, Synthetic Analogs.

INTRODUCTION

Inflammation is the first step of the body's immune reaction against disruption to its cells or tissue by any stimulus, *viz.* infection, bacteria or adverse stimuli. Our

These Authors Contributed equally

Atta-ur-Rahman, *FRS* (Ed.) All rights reserved-© 2021 Bentham Science Publishers

^{*} **Corresponding author Mubashir Hussain Masoodi and Roohi Mohi-ud-din:** Pharmaceutical Chemistry Division, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar-190006, Kashmir, India and Pharmacognosy Division, Department of Pharmaceutical Sciences, University of Kashmir, India; Tel: 9419 0765 25; E-mails: mubashir@kashmiruniversity.ac.in and roohisofi@gmail.com

214 Frontiers in Natural Product Chemistry, Vol. 8

Shah et al.

immune system acts in response to these infections and initiates a healing mechanism called inflammation. Inflammation is, thus, simply a type of defensive process which is required by our body to reduce infection or damage [1]. Generation of pro-inflammatory factors, innate immune cell infiltration, and tissue destruction are implicated in inflammation. The four key symptoms of inflammation are redness, heat, pain, and swelling [2]. The response of immune system to destructive factors, viz. bacteria, toxic compounds, infected cells, is inflammation, which works by eliminating and activating the repairing mechanism by removing injurious stimuli. Therefore, inflammation is a protective process that is significant for our wellbeing. Typically, in the case of inflammatory reactions of acute nature, molecular and cellular process interactions mitigate acute risk effectively. This prevention process leads to the regeneration of the tissue's homeostasis, thus resolving inflammation of acute nature. Unregulated acute inflammation, however, can become chronic, leading to a number of inflammatory disorders of chronic nature [3]. Several forms of microcirculatory activities that alter during inflammation are vascular permeability, mobilization of white blood cells and their aggregation, and release of inflammatory mediators [4, 5]. Inflammation can be chronic or acute and is made up of several mechanisms. Our body seeks to maintain tissue homeostasis in the case of acute inflammation and if acute inflammation turns to be extreme, it may cause chronic inflammation [6]. Tissue damage caused by different pathogenic agents can trigger inflammation. The etiology of inflammation may be contagious or non-infectious. The body starts a chemical signaling pathway in response to tissue injury, which induces responses directed at repairing injured tissues. Such signals activate the leukocyte chemotaxis from the general circulation to sites of injury. Cytokines formed by these activated leukocytes induce inflammatory responses [7]. The organized incitement of signaling pathways in resident tissue cells and inflammatory cells recruited from the blood is an inflammatory response controls inflammatory mediator levels [8]. The prevailing pathogenesis of most chronic disorders is inflammation, including coronary and gastrointestinal diseases, arthritis, asthma and cancer. While inflammatory response mechanism depend on the exact nature of the initial stimuli and its position in the body, they all share a similar pathway that can categorized as (a) cell surface pattern receptors identify harmful stimuli (b) trigger inflammatory cascade (c) release mediators of inflammation and (d) recruit inflammatory cells [9].

Inflammatory reaction may be regulated by removing inducers, blocking sensors, inhibiting markers, else acting straight on target tissues [10]. Removal of inducers, in specific ailing conditions, can require longer duration drug therapy; subsequently, in such situations, the regulation of inflammation through the optimum usage of anti-inflammatory drugs is necessary to avoid remodeling of

Coumarin Derivatives

tissue [11]. Inflammatory mediators such as arachidonic acid metabolites (such as leukotrienes and PGE₂), cytokines, histamine, plasma proteases, serotonin, chemokines, nitric oxide, and colony-stimulating factors are the most commonly researched inflammatory regulation targets. Various pathways, including cyclooxygenases, kinases and caspases (such as cyclin-dependent kinases, Janus kinases, serine threonine kinases, mitogen-activated protein kinases/extracellular signal-regulated kinases, mitogen-activated protein kinases 38, c-jun N-terminal kinases, NF-k β , and lymphocyte-specific kinases are used to produce these mediators. It is stated that the inflammatory mechanism is inhibited at one stage or another by a wide variety of chemicals obtained from a complex population of heterocyclic nuclei [12, 13]. A significant class of anti-inflammatory molecules comprises coumarin analogs. Several researchers have documented that several variants of coumarin at different steps inhibit inflammation [14].

COUMARINS

Coumarins form an exclusive community of compounds in nature that inhibit a special location. Coumarins, along with a number of other chemicals, are pharmacologically flavonoids. A number of biological and pharmacological behaviors have been found to be exhibited by coumarins. Coumarins and their derivatives have gathered significant concern because of their possible useful outcomes on human health [15 - 17]. As a consequence, coumarins and their derivatives have been studied in detail. The basic capacity of certain coumarin derivatives is affecting free radical damage and scavenging of reactive oxygen species. They were also shown to inhibit the peroxidation of lipids and exhibit anti-inflammatory activity. In addition, coumarin and associated derivatives have been used as an inhibitor of arachidonic acid synthesis pathways for lipoxygenase (LOX) and cyclooxygenase (COX) [18]. Coumarin, naturally found in many plants, is an aromatic chemical. Coumarins are especially found in cinnamon and tonka beans in foodstuffs. Many medicines have used the bioactivity of coumarins [19]. Coumarins have also demonstrated useful outcomes in decreasing the incidence of certain malignancies, coronary and brain diseases [20]. However, these are considered to show hepatotoxicity at higher doses [21]. Few coumarin derivatives have shown beneficial parasitic effects and act as phytoalexins that can rapidly accumulate when parasitic infections occur. Psoralen (a furanocoumarin) has anti-arthritic, anti-inflammatory, and anti-microbial properties [22]. While esculetin has been documented in shielding single-cell DNA from various oxidative attacks. Esculetin facilitates the regulation of vasoconstriction, overpowers the transcription factor of Sp1 and gets attached to β -catenin proteins by reducing the release of nitric oxide, resulting in suppression of the signaling process of β -catenin-Tcf gastrointestinal tumorigenesis and also

Recent Progress in the Synthesis and Biological Activity of Chromene and Its Derivatives

Hossein Eshghi^{1,*}, Fatemeh Pirani¹ and Mahsa Khoshnevis¹

¹ Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 91775-1436, Iran

Abstract: Heterocycles have a crucial role in the design and discovery of active pharmaceutical ingredients. Chromenes are heterocycles containing oxygen that are abundantly found in nature and have attracted much attention because of their interesting drug activities. Chromene and its derivatives cover an extensive range of biological properties such as antibacterial, anti-inflammatory, anti-HIV, anti-cancer, anti-oxidant and antimicrobial properties. Regarding the numerous investigations conducted on these valuable compounds during the past few years, we have also pointed to the advances of the last five years in the field of the synthetic and biological importance of these compounds. Concerning the high importance of synthesis of chromene and its derivatives by synthesis methods of 2H-chromenes, 4H-chromenes, benzochromenes, benzopyrans and fused-chromenes, we mentioned that this issue includes the necessity of using various catalysts in mild conditions and/or in microwave conditions. In the following, concerning the very high biological importance of chromenes, we implied some biological properties, including anticancer, anti-inflammatory, anti-oxidant and antimicrobial activities, which indicated that the considered results could be promising and effective for the use of chromene derivatives in the field of drug design. Ultimately, we mentioned several vital methods and strategies include green synthesis and multi-component reactions in various categories for the general synthesis of various types of chromene derivatives. In economical, efficient, green and mild conditions, the above-said methods can synthesize high-efficiency products of chromene and its derivatives in a short period of time.

Keywords: Anti-Cancer Drug Activities, Anti-HIV, Anti-Oxidant, Antibacterial, Active Pharmaceutical, Biological Properties, Chromenes, Heterocycles, Nature.

Atta-ur-Rahman, *FRS* (Ed.) All rights reserved-© 2021 Bentham Science Publishers

^{*} Corresponding author Hossein Eshghi: Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 91775-1436, Iran; E-mail:heshghi@um.ac.ir

INTRODUCTION

The oxygen-containing heterocycles [1 - 8] are among important compounds, which are found in natural products and have interesting biological activities [9 -12]. Over the past few years, chromene [13 - 17] and its derivatives have been significantly considered due to the wide range of biological properties [18 - 26]. These compounds are found in the structure of natural products and also have extensive medicinal properties with wide applications in synthesis of organic compounds. Chromenes are important compounds in oxygen-containing heterocycles. The chromene ring contains a benzene ring welded to the pyran ring. Chromenes play an important role in medicinal chemistry. The high drug potential and the fact that these compounds are low in toxicity have led to a great deal of interest in the synthesis of chromene derivatives in recent years. These compounds play an important role in the design of pharmaceutically and biologically active compounds. The two isomers of chromene are shown in the Fig. (1), which according to IUPAC rules [27] are scored from the side of the ring with heteroatom. The great importance of these compounds in the field of medicine, biology and the synthesis of organic compounds has led us to mention the synthesis strategies of a number of important chromene derivatives and their biological properties.




Fig. (1). The two isomers of chromene.

SYNTHESIS OF CHROMENE DERIVATIVES

Synthesis of 2H-Chromenes

2H-chromenes are important compounds which have shown biological activities. Because of their importance, some trustworthy methods for the synthesis of 2H-chromene derivatives have been developed [28 - 35].

kamazani's group used mesoporous Cu-SBA-15 as nanocatalyst for synthesis of 2H-chromene dyes by reacting 5-phenylazo-salicylaldehyde with acetylacetone in $CH_2Cl_2/EtOH$; 2:1 in high yields (Fig. 2) [36].




Fig. (2). The synthesis of azo-chromene dyes.

Li *et al.* demonstrated that different 2H-chromenes were synthesized in one step by carbene insertion reaction of aryldiazoacetates and (E)-2-hydroxy cinnamaldehydes by using $Rh_2(esp)_2$ with Na_2CO_3 as additive in the presence of CH_2Cl_2 at room temperature in good yields (Fig. 3) [23].




Fig. (3). The synthesis of 2H-chromenes.

In 2018, Asheri and co-workers reported the reaction of diethyl acetylenedicarboxylate, triphenylphosphine and 5-bromo-2-hydroxybenzaldehyde acid in the presence of dichloromethane at room temperature (Fig. 4) [37].




Fig. (4). The synthesis of diethyl 6-bromo-2H-chromene-2,3-dicarboxylate.

Synthesis of 4H-Chromenes

4H-chromenes are found in several natural compounds that have displayed numerous medical activities [38]. Many researchers are interested in the synthesis of 4H-chromenes derivatives [39 - 64].

SUBJECT INDEX

A

Acetylcholinesterase 191 Acid(s) 9, 11, 15, 18, 19, 21, 24, 28, 31, 57, 58, 61, 153, 154, 161, 162, 176, 179, 181, 183, 184, 185, 186, 187, 190, 191, 192, 197, 216, 252, 260, 266, 267, 270 acetylsalicylic 179 alpha-lipoic 183 arachidonic 153 benzenesulfonic 252 benzoic 154 caffeic 31, 161, 183, 192, 197 carboxylic 57, 216 chlorogenic 185, 186 gallic 15, 19, 28 glucuronic 9 guluronic 24 hydrolysable 154 kojic 266, 267 lactic 197 mannuronic 21, 24 maslinic 197 nucleic 176 oleanolic 183, 192, 197, 260 palmitic 18 phenolic 15, 147, 152, 163, 180, 185 phydroxycinnamic 197 propionic 57 rosmarinic 181, 183, 184, 187, 190, 191, 192, 197 thiobarbituric 162, 270 tormentic 183 uronic 11, 24 ursolic 183, 187, 192, 197 Action 18, 146, 155, 154, 158, 161, 216, 229 anti-convulsant 161 anti-influenza 18 antispasmodic 216 neuroprotective 146, 155, 158 ulcerative 229 vasorelaxant 154

Activation 153, 155, 158, 159, 161, 183, 184, 188, 189, 192, 193, 194, 197, 198 microglial 161, 163 proteolysis 217 Activator, monoamine transporter 184 Active carbon nucleophiles 249 Activity 9, 10, 11, 12, 21, 22, 49, 50, 51, 52, 53, 102, 115, 154, 155, 157, 181, 182, 188, 193, 194, 197, 214, 216, 220, 221, 224, 259, 257 agonistic 115 analgesic 102, 221 anti-cancer 257 anti-cholinesterase 181 antifungal 53 anti-neurotoxicity 155 antioxidative 157 anxiolytic 182, 197 cholinergic 193 endocytic 216 microcirculatory 214 vasodilative 49, 50 Adenosine receptor blocker 182 Algae metabolites 3, 32 Alkaloid isomers 48 Alkaloids 61, 92, 105, 123 cinchona 105, 123 macrocyclic 61 quinlozidine 92 Allergic rhinitis 183 Alpha-lipoic acid (ALA) 183 Alzheimer's Disease 159, 160, 174 Amyloid precursor protein (APP) 160, 185, 193 Angiotensin converting enzyme (ACE) 154 Anhydrogalactose 13 Anticancer activity 9, 51, 254, 255, 256, 257, 258 Anti-cancer drug activities 239 Anti-cholinesterase 189 Anti-DENV activity 22 Anti-epileptic drugs (AEDs) 187

Atta-ur-Rahman, FRS (Ed.) All rights reserved-© 2021 Bentham Science Publishers

306 Frontiers in Natural Product Chemistry, Vol. 8

Antigen-presenting cells (APCs) 4 Anti-HCV activity 23 Anti-herpes activity 17 Anti HIV1 activity 26 Anti-hyperlipidaemia 192 Anti-hypertensive 154 activity 154 agents 154 Anti-infective agents 2 Anti-inflammatory104, 105, 119, 153, 179, 192, 213, 215, 218, 219, 220, 221, 223, 224, 227, 228, 229, 231, 258, 259, 260, actions 192, 224, 227 activity 153, 213, 215, 218, 219, 220, 221, 224, 227, 228, 229, 231, 258, 259, 260 agents 153, 179, 213, 219, 223, 227, 229 effects 104, 105, 119, 195, 220, 223, 227, 229 Antimicrobial 3, 48, 52, 239, 266, 267 activity 48, 52, 239, 266, 267 properties 3, 239 Anti-neurotoxicity activity 155 Antioxidant 146, 151, 180, 181, 182, 187, 189, 190, 192, 193, 195, 197 agents 197 endogenous 190 properties 103, 152, 187 Anti-oxidative activity 151 Antioxidative stress activity 191 Anti-stress property 188 Anti-tau protein misprocessing 181 Antituberculosis activity 51 Antitumor activity 66 Antiviral action 4, 9, 11, 13, 18, 20, 21, 23, 32 of polyphenol 32 Apoptosis 151, 155, 157, 256 Arachidonic acid (AA) 153, 215 Aromatherapy 190, 195 Aspergillus fumigatus 54 Aspergillus niger 54 Avian influenza virus (AIV) 23, 30

B

Bacillus subtilis 50 Baek's method 71 Benzaldehyde derivatives 272 Benzochromene derivatives 244 Bioactive phytochemicals 146 Biological activities 146, 151, 253 of phenolic compounds 146, 151 of chromenes 253 Biopolymers of algae 5 Bioprospecting efforts 3 Biosynthetic 63, 64 hypothesis 63 pathway 64 Blocking edema fluid 216 Blood-brain barrier 156 Bronchitis 185, 187 Butyrylcholinesterase 189

С

Cancer 23, 105, 112, 214, 256 human colon 256 liver 256 Candida albicans 54 Catalase 162, 190 Catalysed hydrolysis 61 Catalyst 239, 242, 244, 245, 246, 247, 248, 255, 257, 261, 269, 271, 273, 275, 277 Catalytic synthesis of chromenes 274 Catalyzed 76, 275 hydrogenolysis 76 one-pot synthesis 275 Catholic monasteries 178 Cell death 161, 173, 174, 176, 184, 189, 198 neuronal 161, 173, 198 pathogenesis 174 Cellular 10, 174 apoptosis Interrelation 174 transcription machinery 10 Cellulose 7, 8 Central nervous system (CNS) 100 Cerebellar granule neurons (CGNs) 191 Chemical(s) 155, 196 oxidants 196 neurotoxic 155 Chemoisosteric environments 111 Chinese herbal medicine 179 Choline acetyltransferase 188 Cholinergic neurotransmission 181, 182, 196 Cognitive 115, 181, 194 impairments 181, 194 processes 115 Comins' reagent 67 Conjunctivitis 258 **Constipation 183** Consumption of natural medicine 198

Atta-ur-Rahman, FRS

Subject Index

Coptis japonica 104 Cortical 116, 118 electrical activity 116 thickness (CT) 118 Cryptococcus neoformans 54 Cyclooxygenase 215, 216, 218 Cytokines 4, 119, 153, 175, 190, 195, 196, 214, 215, 216 block 216 inflammatory 119, 229 pro-inflammatory 119, 175, 190, 195, 196 Cytotoxicity 19, 21, 26, 27, 46, 47, 51, 91, 185, 190, 256 Cytotoxic lymphocytes 12

D

Dementia 159, 175, 179, 180, 183 Dendrites outgrowth 194 Dendritic cells (DCs) 4, 5, 12 Depressive disorder 114 Deprotonation 76 Diabetes 123, 124, 187, 189, 191, 216 Diabetic neuropathy 191 Diarrhoea 187, 195 **Diastereomers** 61 Dictyota 25, 26, 29 algae 26 bartayesiana 25 dichotoma 29 menstrualis 26 Diseases 100, 112, 113, 156, 176, 179, 183, 191, 193, 214 age-deteriorating 179 gastrointestinal 183, 214 heart 193 life-threatening 113 Disorders 1, 100,112, 123, 117, 121, 146, 147, 153, 162, 174, 175, 186, 191, 195, 214 age-associated 175 inflammatory 214 mental 100, 174, 186 neurodegenerative 121, 195 neurological 146, 186, 191 neuropsychiatric 147 psychiatric 112, 123

E

Edema 218, 227

Frontiers in Natural Product Chemistry, Vol. 8 307

ELISA assav 19 Embryonic fibroblasts 20 Enantioselective synthesis 73 Endoplasmic reticulum stress (ERS) 155 Energy sources 111 Envelope protein 20 Environmental toxin 157 Enzymes 9, 20, 25, 30, 102, 104, 108, 188, 193, 194, 197, 216, 227 oxidative 102, 216 transferase 188 Epidermal growth factor receptor (EGFR) 253.254 Equilibration process 60 Essential oil (EO) 181, 182, 183, 189, 191, 195 Esterification 77 Ethanolic hydrochloric acid 57 Excitotoxicity-dependent damages 189

F

Fabric printing 7 Facile one-pot synthesis 252 Factors7, 119, 120, 159, 175, 176, 214, 216, 257 apoptotic 159 destructive 214 dynamic 119 hypoxia-inducible 7 neurotrophic 120, 176 therapeutic 257 tumour necrosis 175, 216 Ferula fukanensis 218, 219 Fever 4, 197 dengue 4 hemorrhagic 4 Fibronectin 9 First-generation Enantioselective Synthesis 66 Fisher indole reaction 91 Food and drug administration (FDA) 114, 179 Fractions, bioactive fucoidan 24 Functional connectivity (FC) 118 Functions 4, 10, 66, 111, 117, 173, 174, 176, 182, 188, 187, 192, 193, 216, 229 cholinergic 193 hepatoprotective 229 memory-enhancing 193 mitochondrial 187 multiple physiological 192

308 Frontiers in Natural Product Chemistry, Vol. 8

G

GABAA 189 benzodiazepines sites 189 GABAergic signalling 189, 194 pathway 194 system 189 Gastroenteritis 25 Glucose 191 metabolism 191 transporter 191 Glutamatergic excitatory activities 197 Glutathione reductase (GR) 162, 196 Glycogen synthase kinase 193 Glycosaminoglycans 9 Glycuronogalactofucans 11

Η

Health, mental 121 Hepatitis 4, 10, 15, 24, 28, 31, 112, 125 Herpes simplex virus (HSV) 2, 9, 10, 15, 18, 27, 30, 31 Heterogeneous catalyst 274, 276 HIV 3, 14 infectivity 14 integrase 3 HIV-1 19, 25, 26, 27, 30 replication 26, 27 reverse transcriptase 25, 30 **RT 19** Homeostasis 153, 174 Human 3, 10, 15, 20, 28, 125, 188, 159, 163, 188, 253 breast carcinoma 253 cerebral microvascular endothelial cells (HCMECs) 188 immunodeficiency virus (HIV) 3, 10, 15, 20, 28, 125 Huntington's disease (HD) 156, 173, 174, 175 Hypothalamic pituitary adrenal (HPA) 188 Hypoxia-inducible factor (HIF) 7

I

Immune responses 3, 4, 5, 12, 16, 106, 158, 159, 176 Immunity 5 adaptive 4

innate 4 Infections 2, 4, 15, 16, 18, 20, 23, 24, 29, 100, 183, 193, 213, 214 fungal 183 urinary tract 193 Inflammation 119, 153, 157, 195, 196, 197, 213, 214, 215, 216, 219, 222, 223 amelioration 223 induced damages 196 pathway 195 effects 157 processes 119 Inflammatory response 14, 18, 175, 182, 184, 187, 214 Influence APP processing pathway 182 cell adhesion 14 cooking methods 187 Influenza 5, 19, 21, 29, 32 infection 32 pandemic 5 virus infection 19, 21, 29

J

Japanese encephalitis virus (JEV) 18, 28

K

Klebsiella pneumonia 50 Knoevenagel reaction 262

L

Lateral sclerosis 160, 162 Lipophilicity profile 110 Lipopolysaccharides 153, 189 Lipoproteins 20 Lipoxygenase 215, 216, 218 Loss 159, 163 associated synaptic 159 grey matter tissue 163 Lowand middle-income countries (LMICs) 124, 125 Low transition temperature mixtures (LTTMs) 249 Lymphocytes 11 Lyophilization 127 Lysergic acid diethylamide 113

Atta-ur-Rahman, FRS

Subject Index

Μ

Macrocyclization 57, 59 Macrolactam 59 Macrophage 153, 216 cells 153 migration 216 Major histocompatibility complex I (MHCI) 4 Marine 1, 2, 3, 4, 6, 7, 9, 11, 14, 15, 17, 32, 33, 45, 46, 56, 57 algae 4, 15 alkaloids 45 derived algae 32 ecosystem 2 environment 3, 46 fungi 56 metabolites 3, 9 phytoplanktons 1, 3, 33 polysaccharides 3, 4, 11, 32 Mechanisms 25, 104, 105, 113, 119, 128, 152, 153, 157, 173, 179, 198, 214, 215, 256, 263 anti-inflammatory 119 biological defense 153 cellular death 173 healing 214 inflammatory 215 neurobiological 113 neuroprotective 198 Mediators 153, 159, 198, 214, 215, 229 inflammatory 159, 214, 215 pro-inflammatory 153, 229 Medications, traditional 198 Medicinal plants 125, 177, 178, 179, 180, 193, 195 Medicinal scaffold 258 Medicines 101, 178 psychedelic 101 traditional Chinese 178 Mekabu fucoidan (MF) 21, 29 Memory 12, 157, 179, 186, 188, 187, 192, 194, 196 disruption 157 dysfunctions 194 function 187, 192 restoration 192 Mental 186 fitness 186 Mental health 99, 113, 120 conditions 113, 120

problems 99 Metabolites 2, 8, 9, 33 48, 106, 108, 188, 215 algal 33 arachidonic acid 215 Metabolome 107, 108 Metalloproteinase 185 Michael 74, 259 addition 259 reaction 74 Microorganisms, pathogenic 20 Microtubule-associated protein tau (MAPT) 193 Microwave 242, 276, 277 assisted synthesis of chromenes 276 irradiation 242, 277 Mild cognitive impairments (MCI) 186 Mitogen-activated protein kinase (MAPK) 155, 183, 215 Moderate antiviral activity 22 Monoamine oxidase 182, 194 Monoaminergic 186, 197 hypofunctional state 197 system dysfunction 186 Monocotyledons 8 Mood disorders 119, 187 Motor neurons 160, 191 MTPA method 50 MTT assay 24, 253 Multicomponent domino reaction (MDR) 277 Multiple sclerosis (MS) 158, 160 Multi-target drugs 109, 112 Murine leukemia virus 10 Murine macrophages 189, 197 Mycobacterium tuberculosis 51 Myocardial dysfunction 151, 153, 229

Frontiers in Natural Product Chemistry, Vol. 8 309

Ν

Natural product antifoulants (NPAs) 53 Nerve growth factor (NGF) 194 Networks 101, 118 complex biological 101 dorsal attention 118 Neural plasticity 116, 117 functional 116 induction 117 Neuraminaidase 23 Neuraminidase 25 Neurochemical deficiency 156 Neurodegenerative 146

310 Frontiers in Natural Product Chemistry, Vol. 8

Neurodegenerative diseases 119, 123, 146, 147, 151, 155, 158, 173, 174, 179, 184 Neuroendocrine Effects 119 Neurogenesis 116, 117, 181, 182, 183, 184, 188, 193, 192, 194, 197 hippocampal 193, 197 signalling pathway 192 Neuroimaging 117 Neuroinflammation 159, 173, 174, 175, 176, 195 Neurological 158, 189 diseases 189 dysfunction 158 Neuronal death 174, 176 Neuropathy 216 Neuroprotective 146, 147, 151, 156, 180, 183, 190 activities 156, 180, 183, 190 approaches 147, 151 effects of polyphenols 146 Neurotoxicity 155, 163, 184, 187, 194, 196 Neurotoxins 187, 196 Neurotransmission system dysfunction 173 Neurotransmitters 194 Nitric oxide synthase 153, 217 NMDA-dependent signalling molecules 197 Noninteractive hypothesis 9, 11, 106

0

Onepot multicomponent protocol synthesis 251 One-pot 248, 249 multi-component reaction 249 three-component synthesis 248 Orthoester-Claisen rearrangement 68, 70 Oxidative stress 151, 152, 154, 163, 174, 176, 184, 186, 187, 190, 191, 194, 196 biomarkers 163, 190 cytotoxicity 184 damage 194 hyperglycaemia-induced 187

P

Pain 112, 178, 179, 189, 214, 216 childbirth 178 rheumatic 189 Papilloma virus 15 Parkinson's disease (PD) 74, 156, 157, 158, 174, 175 Patchouli oil 195 Pathogen-associated molecular patterns (PAMPs) 5 Pathways 112, 119, 153, 155, 157, 160, 175, 176, 183, 184, 185, 214, 215, 217 amyloidogenic 184 anti-inflammatory 175 arachidonic acid synthesis 215 cellular signalling 175 disrupted signalling 176 downregulated toxic amyloidogenic processing 185 inflammatory 157 non-amyloidogenic 160 shikimic acid 217 Penicillium citrinum 47 Phagocytic processes 218 Phagocytosis 216 Phenolic compounds (PCs) 15, 146, 147, 148, 149, 151, 152, 153, 154, 155, 156, 157, 158, 162, 163 Photosynthesis 8 Plant-based medicines 179 Plasma proteases 215 Plasmodium falciparum 51 Polysaccharides 9, 11, 20, 21, 22, 24, 182, 194, 197 acidic 11 antiviral 9 heterogenic 11 Positron emission tomography (PET) 118 Prostratin genes 125 Proteinase inhibitors (PI) 102 Protein kinase 159, 184, 197 A (PKA) 197 calcium-dependent AMP-activated 159 G (PKG) 184 Proteins 4, 10, 104, 105, 107, 108, 112, 119, 159, 160, 161, 174, 175, 176, 183, 185, 190, 193, 195, 217 aberrant 174, 175, 193 amyloid precursor 160, 185 apoptotic 190 carbohydrate-binding 14 cyclic-AMP response element-binding 159 domain-containing 185 heat shock 161 misfolded 175, 176

Subject Index

non-structural 10 plasma 217 toxic 195 transactivator 10 viral 4, 10 Proteome 19, 107 rectal mucosal 19 Proteomic analyses display 107 Protocatechuic acids 152 *Pseudomonas fluorescence* 50 Psychoactive ethnobotanicals (PE) 99, 100, 101, 112, 113, 114, 115, 117, 118, 119, 120, 121, 122, 123, 127 Psychologists 100 Psychoplastogens 116

Q

Quinolizidine 45, 46, 47, 71, 74, 75, 76 alcohols 71 skeleton 76

R

Reaction 61, 241, 248 carbene insertion 241 enzyme 153 immune 213 inflammatory 214, 216 pathway 58, 59, 63, 65, 69, 73, 74, 75, 78, 79, 80, 81, 87, 88, 89 Reactive 113, 114, 152, 153, 163, 175, 194, 215 astrogliosis 163 nitrogen species (RNS) 152, 153 oxygen species (ROS) 113, 114, 152, 153, 175, 194, 215 Replicating protein motifs 111 Replication cycle 3 Reverse transcriptase (RT) 11, 15, 24, 25, 30

S

Saccharina 5, 7, 11, 20, 28 cichorioides 5, 20 japonica 7, 11, 20, 28 Salvia 112, 178, 180, 185 divinorum 112 officinalis 178, 180

Frontiers in Natural Product Chemistry, Vol. 8 311

Scardica tea 185 Severe acute respiratory syndrome (SARS) 5, 15.33 Signal-regulated kinases 215 Single-photon emission computed tomography (SPECT) 118 Stress 15, 188 chronic 188 reducing 188 response 188 Superoxide dismutase 157, 162, 190 Synaptic 174, 176, 181, 183, 187, 189, 193, 194 dysfunctions 174, 176 plasticity 181, 183, 187, 189, 193, 194 Synaptogenesis 194 Synthesis 73, 264 catalytic 264 stereoselective 73 Synthesis of 73, 77, 243, 244, 246, 248, 249, 257, 270, 272 benzochromenes 243, 244 benzopyrans 246, 248 calvepictines 77 chromeno 249, 272 dihydropyrano 257, 270 piperidine 73 tetrahydrobenzo 248 Xestospongin Alkaloids 61

Т

Tau protein 23, 159, 176 Therapeutic agents 23, 159, 179 Tissue 214 damage 214 destruction 214 Toll-like receptors (TLRs) 4, 20 Transcription factor 215 Tumour necrosis factor (TNF) 175, 216 Turbinaria decurrens (TD) 25

U

Upregulated B-cell lymphoma 190 Upregulating erythropoietin 161

Atta-ur-Rahman, FRS

V

Vaccines 4, 5, 23, 33 antiviral 4, 33 next-generation influenza 5 Viral 2, 3, 4, 8, 11, 17 infections 4, 8, 11, 17 polymerase 2, 3 reverse transcriptase 11 Virucidal assay 19 Virus 2, 3, 4, 7, 10, 11, 15, 18, 19, 20, 22, 23, 24, 25, 30, 31, 32, 125 anti-human immunodeficiency 3 chikunguniya 7 dengue 22 flu 20 herpes simplex 2 human immunodeficiency 10, 125 measles 19, 24, 30 Vomiting 122

W

Wittig-Homer reaction 74 World health organization (WHO) 179

Х

Xanthine oxidase 152, 182, 194, 216



PROF. DR. ATTA-UR-RAHMAN, FRS

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 - 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.